Because pretransplant blood transfusions (BT) can immunosuppress renal allograft recipients, thereby enhancing graft survival, recent studies have sought similar BT-related immunosuppression (IMS) to tumor antigen in cancer patients, looking for decreased tumor-free and actual survival in patients who received BT. Clinical reviews of colorectal, breast, lung, and other tumors have reported mixed results. While animal studies may eliminate confounding variables that confuse clinical reviews, results from these have also been mixed: both BT-related inhibition and enhancement of tumor growth have been reported. Importantly, most animal studies used a transfusion/antigen sequence more similar to clinical transplantation (BT followed by transplant Ag) than to clinical oncology (tumor Ag followed by BT). Because of this dissimilar BT/Ag sequence, factors that were critical in producing BT-related IMS in transplantation studies may not apply to BT-related IMS in tumors. We studied the factors that may produce BT-related IMS in tumor growth by controlling the timing, volume, and number of transfusions of either saline or syngeneic or allogeneic blood in two murine models. Serial measurements were made to assess the longitudinal BT-related effects on tumor growth.
|Number of pages||4|
|State||Published - 1988|